Pfizer is here to help your patients access their prescribed TUKYSA tablets

Seagen Secure®
offers patient support
Co-Pay Assistance
Eligible, commercially insured patients may pay as little as $0 per month for TUKYSA. Limits, terms, and conditions apply.* Patients may receive up to $10,000 per product in savings annually. There are no income requirements to enroll.
Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico.
Terms and conditions for the TUKYSA® (tucatinib) tablets trial voucher program: 1. Voucher is valid for one 30-day trial. Only patients who are new to TUKYSA therapy are eligible to use the voucher. 2. By redeeming the voucher, you certify that you are not currently taking TUKYSA and have not previously taken TUKYSA. 3. The voucher may not be transferred, sold, purchased, traded, or counterfeited. 4. An original voucher and a valid prescription must be presented to the pharmacy. 5. The voucher will be accepted only at participating specialty pharmacies that are authorized to dispense TUKYSA. 6. You must not submit any claim for reimbursement for product dispensed pursuant to this voucher to any third-party payor, including Medicare, Medicaid, or any other federal or state health care program. You cannot apply the value of the free product received through this voucher toward any government insurance benefit out-of-pocket spending calculations, such as Medicare Part D True Out-of-Pocket Costs (TrOOP). 7. You must be 18 years of age or older to redeem the voucher. 8. The voucher is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance. 9. The voucher is not valid where prohibited by law. 10. The voucher cannot be combined with any other savings, free trial or similar offer for the specified prescription. The voucher should not be combined with samples for the specified prescription. 11. The free trial voucher is not health insurance. The free trial voucher may not be used to address delays or gaps in health insurance coverage for the specified prescription. 12. Offer good only in the United States and Puerto Rico. 13. No purchase is necessary. 14. No membership fees. 15. Patients have no obligation to continue to use TUKYSA. 16. Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
How to fill a TUKYSA prescription
Specialty pharmacies
- Biologics
- Onco360
In-office dispensers
(Medically integrated dispensaries)
(Medically integrated dispensaries)
IDN specialty pharmacies + hospital pharmacies
Physician practices can obtain TUKYSA from one of the following
specialty distributors:
-
ASD HEALTHCARECall 800-746-6273 | Fax 800-547-9413Visit asdhealthcare.com
-
CARDINAL HEALTH SPECIALTY DISTRIBUTIONCall 855-740-1871 | Fax 888-345-4916Visit cardinalhealth.com
-
MCKESSON PLASMA AND BIOLOGICS, LLCCall 877-625-2566 | Fax 888-752-7626Visit mckesson.com
-
MCKESSON SPECIALTY HEALTHCall 800-482-6700 | Fax 800-800-5673
-
ONCOLOGY SUPPLYCall 800-633-7555 | Fax 800-248-8205Visit oncologysupply.com
These specialty pharmacies are authorized to dispense TUKYSA:
TUKYSA dosage strengths and counts:






Important Safety Information
Warnings and Precautions
-
Diarrhea: TUKYSA can cause severe diarrhea including
dehydration, hypotension, acute kidney injury, and death. If diarrhea
occurs, administer antidiarrheal treatment as clinically indicated.
Perform diagnostic tests as clinically indicated to exclude other
causes of diarrhea. Based on the severity of the diarrhea, interrupt
dose, then dose reduce or permanently discontinue TUKYSA.
In HER2CLIMB, when TUKYSA was given in combination with trastuzumab and capecitabine, 81% of patients who received TUKYSA experienced diarrhea, including 0.5% with Grade 4 and 12% with Grade 3. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. Median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to TUKYSA dose reductions in 6% of patients and TUKYSA discontinuation in 1% of patients. Prophylactic use of antidiarrheal treatment was not required on HER2CLIMB. -
Hepatotoxicity: TUKYSA can cause severe
hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting
TUKYSA, every 3 weeks during treatment, and as clinically indicated.
Based on the severity of hepatotoxicity, interrupt dose, then dose
reduce or permanently discontinue TUKYSA.
In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to TUKYSA dose reductions in 8% of patients and TUKYSA discontinuation in 1.5% of patients. - Embryo-Fetal Toxicity: TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for 1 week after the last dose.
Adverse Reactions
In HER2CLIMB, serious adverse reactions occurred in 26% of patients
who received TUKYSA; the most common (in ≥2% of patients) were
diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and
seizure (2%). Fatal adverse reactions occurred in 2% of patients who
received TUKYSA including sudden death, sepsis, dehydration, and
cardiogenic shock.
Adverse reactions led to treatment discontinuation in 6% of patients
who received TUKYSA; the most common (in ≥1% of patients) were
hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions led to dose
reduction in 21% of patients who received TUKYSA; the most common (in
≥2% of patients) were hepatotoxicity (8%) and diarrhea (6%).
The most common adverse reactions in patients who received TUKYSA
(≥20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea,
hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and
rash.
Lab Abnormalities
In HER2CLIMB, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased phosphate, increased ALT, decreased potassium, and increased AST.
The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.
Drug Interactions
- Strong CYP3A/Moderate CYP2C8 Inducers: Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
- Strong or Moderate CYP2C8 Inhibitors: Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
- CYP3A Substrates: Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
- P-gp Substrates: Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicity.
Use in Specific Populations
- Lactation: Advise women not to breastfeed while taking TUKYSA and for 1 week after the last dose.
- Renal Impairment: Use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (CLcr < 30 mL/min), because capecitabine is contraindicated in patients with severe renal impairment.
- Hepatic Impairment: Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.
REF-T1K1161
Indication
TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Please see full Prescribing Information.
Important Safety Information
Important Safety Information + Indication
Indication
Warnings and Precautions
Warnings and Precautions
-
Diarrhea:
TUKYSA can cause severe diarrhea including dehydration,
hypotension, acute kidney injury, and death. If diarrhea occurs,
administer antidiarrheal treatment as clinically indicated.
Perform diagnostic tests as clinically indicated to exclude other
causes of diarrhea. Based on the severity of the diarrhea,
interrupt dose, then dose reduce or permanently discontinue
TUKYSA.
In HER2CLIMB, when TUKYSA was given in combination with trastuzumab and capecitabine, 81% of patients who received TUKYSA experienced diarrhea, including 0.5% with Grade 4 and 12% with Grade 3. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. Median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to TUKYSA dose reductions in 6% of patients and TUKYSA discontinuation in 1% of patients. Prophylactic use of antidiarrheal treatment was not required on HER2CLIMB. -
Hepatotoxicity:
TUKYSA can cause severe hepatotoxicity. Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.
In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to TUKYSA dose reductions in 8% of patients and TUKYSA discontinuation in 1.5% of patients.
-
Embryo-Fetal Toxicity:
TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for 1 week after the last dose.
Adverse Reactions
In HER2CLIMB, serious adverse reactions occurred in 26% of
patients who received TUKYSA; the most common (in ≥2% of
patients) were diarrhea (4%), vomiting (2.5%), nausea (2%),
abdominal pain (2%), and seizure (2%). Fatal adverse reactions
occurred in 2% of patients who received TUKYSA including sudden
death, sepsis, dehydration, and cardiogenic shock.
Adverse reactions led to treatment discontinuation in 6% of
patients who received TUKYSA; the most common (in ≥1% of
patients) were hepatotoxicity (1.5%) and diarrhea (1%). Adverse
reactions led to dose reduction in 21% of patients who received
TUKYSA; the most common (in ≥2% of patients) were hepatotoxicity
(8%) and diarrhea (6%).
The most common adverse reactions in patients who received
TUKYSA (≥20%) were diarrhea, palmar-plantar erythrodysesthesia,
nausea, hepatotoxicity, vomiting, stomatitis, decreased
appetite, anemia, and rash.
Lab Abnormalities
In HER2CLIMB, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased phosphate, increased ALT, decreased potassium, and increased AST.
The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.
Drug Interactions
- Strong CYP3A/Moderate CYP2C8 Inducers: Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
- Strong or Moderate CYP2C8 Inhibitors: Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
- CYP3A Substrates: Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
- P-gp Substrates: Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicity.
Use in Specific Populations
- Lactation: Advise women not to breastfeed while taking TUKYSA and for 1 week after the last dose.
- Renal Impairment: Use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (CLcr < 30 mL/min), because capecitabine is contraindicated in patients with severe renal impairment.
- Hepatic Impairment: Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.
REF-T1K1161
Indication
TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Please see full Prescribing Information.
TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Please see full Prescribing Information.